The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwNHL 2017 | Exciting advances in checkpoint inhibitors, CAR T-cells and ALK inhibitors
Steven Rosen, MD, from the City of Hope, Duarte, CA, discusses highlights of the 2017 International Workshop in Non-Hodgkin Lymphoma (iwNHL) in Vancouver, BC, Canada. More concrete data had been released for various novel treatments, such as checkpoint inhibitors, CAR T-cell therapies, and ALK inhibitors. Dr Rosen explains that this is a promising and rapidly evolving field, but there are still many challenges ahead.
